These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24631871)

  • 21. Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
    Gottlieb SL; Giersing BK; Hickling J; Jones R; Deal C; Kaslow DC;
    Vaccine; 2019 Nov; 37(50):7408-7418. PubMed ID: 29224963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
    Sandgren KJ; Truong NR; Smith JB; Bertram K; Cunningham AL
    Methods Mol Biol; 2020; 2060():31-56. PubMed ID: 31617171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estradiol improves genital herpes vaccine efficacy in mice.
    Pennock JW; Stegall R; Bell B; Vargas G; Motamedi M; Milligan G; Bourne N
    Vaccine; 2009 Sep; 27(42):5830-6. PubMed ID: 19660586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.
    Halford WP; Püschel R; Gershburg E; Wilber A; Gershburg S; Rakowski B
    PLoS One; 2011 Mar; 6(3):e17748. PubMed ID: 21412438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential impact of a prophylactic herpes simplex vaccine.
    Rupp R; Bernstein DI
    Expert Opin Emerg Drugs; 2008 Mar; 13(1):41-52. PubMed ID: 18321147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.
    Chiuppesi F; Vannucci L; De Luca A; Lai M; Matteoli B; Freer G; Manservigi R; Ceccherini-Nelli L; Maggi F; Bendinelli M; Pistello M
    J Virol; 2012 Jun; 86(12):6563-74. PubMed ID: 22491465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Herpes. Vaccines for HSV.
    Stanberry LR
    Dermatol Clin; 1998 Oct; 16(4):811-6, xiv. PubMed ID: 9891686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
    Awasthi S; Zumbrun EE; Si H; Wang F; Shaw CE; Cai M; Lubinski JM; Barrett SM; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
    J Virol; 2012 Apr; 86(8):4586-98. PubMed ID: 22318147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycoprotein D adjuvant herpes simplex virus vaccine.
    Bernstein D
    Expert Rev Vaccines; 2005 Oct; 4(5):615-27. PubMed ID: 16221064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine.
    Tavares F; Cheuvart B; Heineman T; Arellano F; Dubin G
    Vaccine; 2013 Mar; 31(13):1759-64. PubMed ID: 23313657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?
    Dasgupta G; BenMohamed L
    Vaccine; 2011 Aug; 29(35):5824-36. PubMed ID: 21718746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunology. Painful failure of promising genital herpes vaccine.
    Cohen J
    Science; 2010 Oct; 330(6002):304. PubMed ID: 20947733
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy results of a trial of a herpes simplex vaccine.
    Belshe RB; Leone PA; Bernstein DI; Wald A; Levin MJ; Stapleton JT; Gorfinkel I; Morrow RL; Ewell MG; Stokes-Riner A; Dubin G; Heineman TC; Schulte JM; Deal CD;
    N Engl J Med; 2012 Jan; 366(1):34-43. PubMed ID: 22216840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107
    Khan AA; Srivastava R; Vahed H; Roy S; Walia SS; Kim GJ; Fouladi MA; Yamada T; Ly VT; Lam C; Lou A; Nguyen V; Boldbaatar U; Geertsema R; Fraser NW; BenMohamed L
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond.
    Chang JY; Balch C; Oh HS
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Herpes simplex virus vaccine studies: from past to present].
    Us D
    Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model.
    Kwant-Mitchell A; Ashkar AA; Rosenthal KL
    J Virol; 2009 Oct; 83(20):10664-76. PubMed ID: 19656896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
    Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK
    Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.